








Gastric adenocarcinoma of the fundic gland:
A review of clinicopathological
characteristics, treatment and prognosis
Xiang-yu Meng2,*, Guang Yang1,3,*, Cheng-ji Dong4 and Ru-yi Zheng5
Abstract
Gastric adenocarcinoma of the fundic gland is a rare, well-differentiated gastric cancer entity, and very few patients
transition to poorly differentiated tubular adenocarcinoma during progression. Gastric adenocarcinoma of the fundic gland
originates from the mucosa of the gastric fundic gland, usually without chronic gastritis or intestinal metaplasia. Histo-
logically, the tumor cells are closely arranged to form anastomosing tubular glands, and more than 95% of tumor cells
differentiate towards chief cells. Most gastric adenocarcinoma of the fundic gland cases are characterized by submucosal
involvement, but the tumor volume is usually small, with lymphatic and vascular invasion rarely observed. Therefore,
endoscopic submucosal dissection can be an ideal treatment, leading to a favorable prognosis, and recurrence and
metastasis of the disease are uncommon.
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Introduction
Morphologically, gastric cancer features a wide range of
morphological heterogeneity, resulting in a variety of dif-
ferent histological subtypes.1 According to the Lauren
classification, gastric cancer is classified into intestinal and
diffuse types2; according to the Nakamura classification,
gastric cancer is grouped into differentiated and undiffer-
entiated types.3 Based on molecular and genetic profiling,
gastric cancer is divided into four genetic subtypes: Ep-
steinBarr virus (EBV)infected tumors, microsatellite in-
stability (MSI) tumors, genomically stable tumors, and
chromosomally unstable tumors.4 With the development of
immunohistochemistry (IHC), it has been confirmed that
intestinal gastric cancer contains a gastric phenotype. The
gastric phenotypes include foveolar type, pyloric gland
type, and fundic gland type.
In 2007, gastric adenocarcinoma of the fundic gland
(GA-FG) was first reported as a novel tumor entity by
Tsukamoto et al.5 According to tumor cell differentiation,
GA-FG can be divided into three subtypes: chief cell-
predominant type, parietal cell-predominant type, and
mixed type. The GA-FG chief cell-predominant (GA-FG-
CCP) type accounts for approximately 99% of all GA-FG
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cases.6 With the increasing number of reported GA-FG
cases, the purpose of this review is to summarize the
clinicopathological characteristics, endoscopic appearance,
pathogenesis, molecular phenotype, and prognosis of GA-
FG to increase understanding of clinicians and pathologists
regarding this type of disease.
Clinicopathological characteristics
GA-FG is a rare subtype of gastric cancer with well-
differentiated tissue and clear boundaries, accounting for
approximately 1% of early gastric adenocarcinomas.7 Most
lesions are located in the middle and upper third of the
stomach.8 According to previous studies, the ratio of male to
female patients with GA-FG is approximately 1.49; how-
ever, based on our analysis, the ratio is approximately 2.2.
The GA-FG tumor volume is usually small, approximately
1 cm.10 Most GA-FG patients do not have intestinal
metaplasia, atrophic glands, or Helicobacter pylori (H. pylori)
infection.8,11 However, in our study, according to the available
data, 19 of 67 GA-FG patients had H. pyloripositive in-
fection, and 11 of 48 GA-FGnegative patients experienced
H. pylori eradication therapy. Therefore, we think that the
H. pylori infection should be given more attention as a
factor in GA-FG pathogenesis. GA-FG is a well-
differentiated and low malignant potential tumor. Lym-
phatic and vascular invasion rarely occurs,8,11,12 according
to the Japanese classification of gastric carcinoma. Our
current analysis shows that only 10 (6.3%) of 159 GA-FG
cases with available relevant data had lymphatic invasion,
and only 8 (5.0%) of 160 GA-FG cases had vascular in-
vasion, which is similar to previous studies. Yasuhiro Okunura13
reported a rare case of GA-FG. This was the first report of
GA-FG progressing to aggressive cancer with lymph node
metastasis. More detailed clinical features are presented in
Table 1.
Endoscopic imaging features
Endoscopically, most GA-FG lesions are located in the
middle/upper third of the stomach. According to a previous
review, the proportion of GA-FG lesions located in the
middle/upper third of the stomach is up to 98% among the
total GA-FG cases.6 In our current analysis, the proportion
was approximately 97.4%, which is similar to the previous
results. The number of cases located in the upper, middle,
and lower third of the stomach was 156, 34, and 3, re-
spectively. Macroscopically, according to the available data,
3 tumor lesions showed a protruded type (T0-I); 1 tumor
lesion presented an ulcerative type (T2); and the number of
cases of superficial and elevated (0-IIa), superficial and flat
(0-IIb), superficial and depressed (0-IIc), and mixed type
was 94, 14, 39, and 20, respectively. Narrow band imaging
can enhance visualization of mucosal vessels and show
irregular patterns, which indicate heterogeneity of micro-
vessels in GA-FG.7,14 The use of narrow band imaging and
endoscopic ultrasound can improve the chance of complete
resection through endoscopic mucosal resection (EMR)
technology.
Histopathological features
The histopathological findings for GA-FG are shown in
Figure 1. The tumor surface area is typically still covered
with normal foveolar epithelium. Chronic inflammation,
atrophic glands, and intestinal metaplasia are rarely ob-
served in the surrounding mucosal background. Tumor
lesions are composed of closely arranged and anastomosing
glands, forming an “endless gland.” Tumor cells are similar
to fundic gland cells, appearing as well-differentiated,
mildly heterogeneous columnar cells with moderately en-
larged nuclei. In approximately 99% of cases, tumor cells
differentiate into chief cells.6 In our study, according to the
relevant data available, the number of GA-FG-CCP cases
was 163, accounting for 96%. In addition, 2 cases appeared
to exhibit the foveolar epithelium type, 1 case showed
mixed type differentiation, and 3 cases differentiated to-
wards the mucous neck cell type. GA-FG originates from
the deep layer of the lamina propria. Although most tumor
lesions show submucosal invasion, lymphatic and vascular
invasion is very rare.7,8,15 According to our analysis, among
163 cases of GA-FG, 119 cases had submucosal infiltration
(73%), and only two cases had subserosal infiltration. Al-
though tumor submucosal involvement has been identified
in most reports, thin wisps of muscularis mucosae with the
absence of desmoplasia were identified throughout the le-
sions. Therefore, Singhi et al.16,17 suggested that this change
represents prolapse-type growth to the submucosa rather
than the more typical submucosal infiltration seen with
malignant tumors. Some researchers believe that it is ex-
cessive and exaggerated to name this disease “GA-FG,” and
this type of disease should be considered benign. They
prefer to use “oxyntic gland polyps/adenomas” rather than
“GA-FG.”16 Although Yasuhiro Okumura reported a rare
case of GA-FG that gradually transitioned into aggressive
tubular adenocarcinoma with poorly differentiated com-
ponents in the muscularis propria and subserosal layers,
there were only two cases of subserosal infiltration in our
analysis.13,18
IHC was used to evaluate lineage differentiation in GA-
FG. The main relevant cell differentiation markers are
shown in Table 2. Mucin phenotypes of GA-FG were
identified by detecting the expression of gastric phenotype
markers, such as MUC5AC and MUC6, and intestinal
phenotype markers, such as MUC2 and CD10.19
Pepsinogen-1 is the most specific marker of chief cell
differentiation, and its immunohistochemical analysis will
be necessary for diagnosis of GA-FG-CCP. Previously,
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Fan21 1 60 1/0 0/1/0 1/0/0 5 –– 0/1/0/0 –– –– Chief cell
Li8 8 48–
80
3/5 7/1/0 0/8/0 4–12 6/0/2/0 2/5/1/0 - - Chief cell
Chen11 1 55 0/1 2/0/0 0/0/1 6 and 4 1/1/0/0 2/0/0/0 - - Chief cell
Takeshi12 1 73 1/0 1/0/0 1/0/0 25 1/0/0/0 1/0/0/0 - - Foveolar
epithelium
Yu27 1 77 0/1 0/0/1 0/0/1 6 1/0/0/0 0/1/0 - - Chief cell
Fumiaki15 8 51–
83
4/4 6/2/0 0/4/4 4–14 6/2/0/0 5/3/0/0 - - Chief cell
Keita28 1 76 0/1 –– 1/0/0 28 0/0/1/0 0/1/0/0 - - Chief cell
Atsushi29 1 70 1/0 0/1/0 –– 23 –– 0/1/0 - –– Foveolar
epithelium
Yasuhir13 1 55 1/0 1/0/0 –– 47 T2 0/0/0/1 + + Chief cell
Hitoshi30 1 78 1/0 –– 0/0/1 4 and 7 T0-I 1/1/0/0 - - Chief cell
Shigeo31 1 58 1/0 1/0/0 0/0/1 7 1/0/0/0 0/1/0/0 - - Chief cell
Keitaro32 1 87 1/0 0/0/1 1/0/0 3 T0-I 1/0/0/0 - - Mixed
Takashi26 26 49–
82
19/7 20/6/0 –– 3–39 17/0/5/4 11/15/0 2/24 1/25 Chief cell
Yoriaki33 1 50 1/0 –– 0/1/0 5 1/0/0/0 0/1/0 –– –– Chief cell
Gen34 4 42–
62
2/2 3/1/0 2/2/0 2–5 2/2/0/0 2/2/0 - - Chief cell
Keisuke35 1 62 1/0 0/1/0 0/1/0 –– 0/0/1/0 0/1/0 - + Chief cell
Eleanor36 1 49 1/0 1/0/0 0/1/0 11 –– 0/1/0 - + Chief cell
Takashi25 20 44–
85
16/4 14/6/0 13/5/2 –– 12/5/3/0 –– –– –– Chief cell
Sato37 1 77 0/1 1/0/0 0/1/0 10 1/0/0/0 0/1/0/0 - - Chief cell
Hee3 1 69 1/0 1/0/0 –– 25 –– 0/1/0 - - Chief cell
Soichi38 1 66 1/0 1/0/0 0/1/0 –– 0/1/0/0 1/0/0/0 - - Chief cell
Masaki7 5 67–
78
3/2 5/0/0 0/5/0 5–13 4/1/0/0 0/2/3/0 1/4 - Chief cell
Lee39 11 55–
82
8/3 8/3/0 –– 3–18 T0-I:1; 5/1/4/
0
–– - - Chief cell
Kato40 1 80 1/0 1/0/0 0/1/0 30 1/0/0/0 0/1/0/0 - - Chief cell
Ueyama41 10 55–
78
6/4 6/4/0 */6/1 3–31 */1/3/0 5/4/1/0 1/9 - Chief cell
Nomura10 26 49–
79
22/4 23/3/0 –– 3–85 15/0/5/6 0/20/6/0 3/23 2/24 ––
Ueo18 1 62 1/0 0/1/0 0/1/0 44 –– 0/0/0/1 + + Chief cell
Ryoji42 3 56–
78
1/2 3/0/0 –– 3–8 –– 1/1/1/0 –– –– Chief cell
Hidaka17 31 41–
79
21/10 28/3/0 –– 3–85 14/0/10/7 0/31/0 1/30 1/30 Chief cell
Su park43 3 47–
76
3/0 1/1/1 –– 12–36 0/0/0/3 1/1/1/0 - - Chief cell
Singhi16 10 44–
79
4/6 10/0/0 –– 20–80 –– 10/0/0/0 - - Chief cell: 7;
Mucous
neck cell: 3
Fukatsu44 1 55 1/0 1/0/0 –– 5 –– 0/1/0/0 - - Chief cell
Terada22 1 78 1/0 1/0/0 –– 15 1/0/0/0 –– –– –– Chief cell
(continued)
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Ueyama et al.20 reported that in the tumor progression
process, cell differentiation can change from the fundic
gland type to the foveolar type in advanced GA-FG patients.
GA-FG differentiation in several directions has more ma-
lignant potential than GA-FG differentiation into chief
cells.12
Regarding expression of p53 protein and the Ki67 la-
beling index, none of the reported cases showed an over-
expression of p53, and the Ki67 labeling index was very low
(less than 5%).21,22
Pathogenesis and molecular analysis
Although many studies have been performed to elucidate
the pathogenesis of GA-FG, it is still unclear. H. pylori is a
gram-negative, flagellated, acid-resistant bacterium that
infects more than 50% of the world’s population.23 In
etiology, H. pylori infection is associated with nonatrophic
or atrophic gastritis, intestinal metaplasia,15,24 and peptic
ulcers and is an increased risk factor for developing gastric
adenocarcinoma and mucosa-associated lymphoid tissue
lymphoma.23
A recent study reported the effect ofH. pylori infection in
GA-FG. Compared with the H. pylori-negative group, a
decreasing number of fundic glands and thinned foveolar
epithelium covering tumor ducts were observed in the H.











































6/4 10/0/0 –– 4–20 5/0/5/0 1/6/3/0 - - Chief cell
Total 195 41–
87
134/61 156/34/3 19/37/11 2–85 T0-I: 3; T2: 1;
94/14/39/
20







––: Relevant data is not available; M: male; F: female; U: upper third of stomach; M: middle third of stomach; L: lower third of stomach;H. pylori:Helicobacter
pylori; Type 0-I: protruded type; 0-IIa: superficial and elevated type; 0-IIb: superficial and flat type; 0-IIc: superficial and depressed type; T2: ulcerative; M:
tumor confined to the mucosa; SM1: tumor confined to the submucosa, but depth is within 0.5 mm of the muscularis mucosae; SM2: tumor invasion is
0.5 mm or more deep into the muscularis mucosae; SS: tumor invades the subserosa; +: positive; -: negative; *: partial data is unknown.
Figure 1. Histopathological findings of representative GA-FG case. (A) In low-power view (×40), the tumor originated from the deep
layer of the lamina propria and invaded submucosal layer. The surface was covered with non-atypical foveolar epithelium; (B) and (C):
In high-power view (×100 and 200), the tumor comprised well-differentiated columnar cells mimicking the fundic gland cells with mild
nuclear atypia.
Table 2. Cell differentiation markers.
Marker Cell type targeted
MUC2 Goblet cell
MUC5AC Gastric foveolar epithelium





cases of GA-FG, of which 15 were H. pylori positive or
experienced H. pylori eradication, but almost all lesions
occurred in nonatrophic gastric mucosa. Therefore, the
association between H. pylori infection and GA-FG still
needs to be further studied.
Some GA-FG cases showed distended fundic glands
mixed with foveolar cells, similar to fundic gland polyps.
Therefore, some hypotheses have been raised regarding
whether the occurrence of GA-FG is related to the use of
proton pump inhibitors. However, the associated research is
limited, and the relationship between the occurrence of GA-
FG and the use of proton pump inhibitors is not clear.
There are few studies on the molecular changes asso-
ciated with GA-FG. Activation of the Wnt/β-catenin sig-
naling pathway is considered to be related to GA-FG
occurrence, but the detailed mechanism underlying the
activation of this signaling pathway has not been elucidated.
To elucidate the potential role of gene methylation in re-
lation to the Wnt/β-catenin signaling pathway, Takashi
Murakami et al.26 performed β-catenin immunostaining and
methylation-specific PCR detection of related genes, in-
cluding SFRPs, APC, AXIN2, and MCC, in GA-FG-CCP.
They found that the nuclear β-catenin labeling index was
higher in GA-FG-CCP. SFRPs, APC, and AXIN2 are also
more frequently methylated in GA-FG-CCP. A significant
correlation was observed between nuclear β-catenin ex-
pression and SFRP1 methylation. In conclusion, the acti-
vation of this signaling pathway mediated by gene
methylation may be related to the occurrence and devel-
opment of GA-FG-CCP. In 2014, Ryosuke Nomura et al.10
detected the mutation status ofGNAS and theWnt/β-catenin
signaling pathwayrelated genes CTNNB1/AXINS/APC in 26
cases of GA-FG. They found that nearly half of the cases
harbored at least one mutation in CTNNB1/AXINS/APC,
leading to persistent activation of the Wnt/β-catenin sig-
naling pathway. Among 26 cases of GA-FG, only 5 cases
contained GNAS mutations (R201 C). GNAS mutation may
occur in a small proportion of GA-FG as an alternative
mechanism to activate theWnt/β-catenin signaling pathway.
Similarly, in 2013, Yasuhiro Hidaka et al.17 detected the
mutation status of the CTNNB1/AXIN1/AXIN2/APC genes.
The results showed that 14 (51.9%) of 27 GA-FG-CCP type
lesions contained at least one gene mutation in CTNNB1/
AXIN1/AXIN2/APC. Among 27 cases of GA-FG, 17 cases
presented low nuclear β-catenin expression, and 7 cases had
high nuclear β-catenin expression. Therefore, as a unique
nonaggressive tumor entity, GA-FG-CCP is characterized
by accumulation of nuclear β-catenin and mutation of
CTNNB1 or AXIN genes, indicating activation of the Wnt/
β-catenin pathway. However, in a recent paper on 8 cases of
GA-FG,8 tumor nuclear β-catenin expression was negative
in all cases, which may be attributed to the limited number
of cases.
Treatment and prognosis
GA-FG is a well-differentiated, well-circumscribed, and
low malignant potential gastric cancer entity that rarely
exhibits lymphatic or vascular invasion. However, it is
commonly observed in the submucosa. Endoscopic sub-
mucosal dissection (ESD) is considered the most effective
regimen for restricted GA-FG. The present evidence shows
that GA-FG has a favorable prognosis, and metastasis and
recurrence rarely occur during follow-up. Li et al.8 per-
formed a follow-up of 8 cases of GA-FG from 5 to
33 months. None of the patients had recurrence or metas-
tasis. According to these characteristics, GA-FG confined to
the submucosa can be treated by ESD. However, extended
gastrectomy is needed for GA-FG that has transitioned into
a more malignant tumor, disease with suspected lymph node
metastasis, or multiple gastric cancer.
Conclusion
GA-FG is a well-differentiated, low malignant potential,
gastric cancer entity originating from the gastric fundic
gland. In the surrounding mucosal background, chronic
gastritis, atrophic glands, and intestinal metaplasia cannot
be observed. In more than 95% of GA-FG cases, the tumor
cells differentiate towards chief cells. Tumor cells with mild
atypia and enlarged nuclei are closely arranged to form
anastomosing glands, the so-called “endless gland.” Tumor
lesions are very prone to involve the submucosa, despite
their low malignancy and invasiveness. This phenomenon
may not be malignant invasion of the tumor but instead may
be a prolapse-type growth pattern into the submucosa.
Although abnormal activation of the Wnt/β-catenin sig-
naling pathway is related to GA-FG, there are few studies on
the molecular changes in GA-FG and its pathogenesis, and
further studies on GA-FG pathogenesis are necessary.
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